Alzheimer’s disease therapies in phase III development 2024, by type
As of January 1, 2024, 34 percent of Alzheimer’s disease drugs in clinical trial phase III of development worldwide addressed neurotransmitter receptor mechanisms. This statistic illustrates Alzheimer’s disease drugs in phase III of development worldwide as of early 2024, by type.